JP Morgan Chase
BEAM icon

JP Morgan Chase’s Beam Therapeutics BEAM Stock Holding History

JP Morgan Chase’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-40,700
Closed -$692K – 7392
2025
Q2 		$692K Hold
40,700
– – ﹤0.01% 4604
2025
Q1 		$795K Buy
+40,700
New +$1.07M ﹤0.01% 4495
2022
Q3 		– Sell
-9,600
Closed -$372K – 6457
2022
Q2 		$372K Buy
+9,600
New +$382K ﹤0.01% 4737

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

JP Morgan Chase's BEAM Position: Q2 2026 in Review

JP Morgan Chase reduced its Beam Therapeutics (BEAM) stake by 6.6% in Q2 2026, selling an estimated $1.1M and leaving 514,767 shares worth $18.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2307.

JP Morgan Chase first reported a position in BEAM in Q1 2020 and has held it in 26 quarters since. The position peaked at $67.7M in Q2 2021. 278 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • JP Morgan Chase held 514,767 shares of Beam Therapeutics worth $18.1M as of Q2 2026.
  • JP Morgan Chase sold 36,588 Beam Therapeutics shares in Q2 2026, an estimated $1.1M.
  • Beam Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2307 holding.
  • JP Morgan Chase first reported a position in Beam Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • JP Morgan Chase's Beam Therapeutics position peaked at $67.7M in Q2 2021.
  • 278 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.